NK Cell Production via Three-Stage Cytokine Regimen
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for efficient methods to produce and expand natural killer (NK) cells that retain tumoricidal functions for effective tumor rejection and viral infection control, as existing methods are inadequate in producing high yields of functional NK cells.
Innovation Solution
A three-stage method involving culturing hematopoietic stem or progenitor cells in media with specific cytokines such as thrombopoietin, interleukin-15, and IL-2, without stem cell mobilizing agents and low-molecular weight heparin, to produce NK cells that are CD56+ and CD3-, achieving high viability and cytotoxicity against tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods are used to produce NK cells, then some NK cells can be obtained, but the yield is insufficient and functional activity is compromised
Solution Approach 1:
The patent divides the NK cell production process into three distinct stages with specific cytokine combinations: Stage 1 uses TPO and IL-15 for initial expansion, Stage 2 introduces IL-2 to maintain tumoricidal function, and Stage 3 uses IL-15 alone for final maturation. This segmented approach allows optimization of each stage for specific outcomes, achieving both high yield and functional retention.
Solution Approach 2:
The patent systematically changes cytokine parameters across the three stages: TPO concentration is maintained at 5-50 ng/mL in Stage 1, IL-15 at 10-100 ng/mL, then IL-2 is added at 100-1000 U/mL in Stage 2, and finally only IL-15 is maintained in Stage 3. These parameter changes drive the differentiation and functional maturation of NK cells while maximizing yield.
2Productivity
If stem cell mobilizing agents and low-molecular weight heparin are included in culture media, then cell expansion may be enhanced, but cell viability and functional quality deteriorate
Solution Approach 1:
The patent explicitly removes stem cell mobilizing agents (such as G-CSF) and low-molecular weight heparin from the culture media, demonstrating that these components are not necessary for NK cell production and may actually harm cell quality. The three-stage cytokine regimen achieves expansion without these potentially harmful additives.
Solution Approach 2:
The patent replaces complex, potentially harmful media components with simple, well-defined cytokine combinations that are easier to control and less likely to compromise cell quality. The use of standardized cytokines (TPO, IL-15, IL-2) at defined concentrations provides a cleaner, more controllable production system.
Data Source
Figure 1A~1C
Figure 2
Figure 2
AI summary
Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.